Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'
March 19, 2024 2:50 PM EDTEvercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining a Outperform rating.
The analyst comments "With clean label in hand & an additional $600M in the bank, Madrigal is well positioned to execute on the... More
